Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office

We're thrilled to share our latest news!

Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office to maintain Medivation/Astellas formulation patent EP3725778 B1 covering Xtandi® tablet formulation, which represents a relevant barrier for Generics.

What sets our innovation apart? Our proprietary nanoenzalutamide tablet formulation has been developed as an alternative to the amorphous solid dispersion to enable a more patient-centric alternative to Xtandi® tablets and paves the way for a timely market entry as early as 2028.

This shows the commitment to innovation of the ONConcept® consortium (Bluepharma, HELM AG and WELDING GmbH & Co. KG) in partnership with Nanoform and our relentless pursuit of advancing healthcare solutions.

Stay tuned!